Business Wire

CA-QUANERGY-SYSTEMS

Share
Quanergy Secures First AI-Powered 3D LiDAR Integration with Industry Leading Security Center Platform From Genetec

Quanergy Systems, Inc. , a leading provider of LiDAR (Light Detection and Ranging) sensors and smart perception solutions, today announced the first commercial integration of 3D AI-powered LiDAR solutions with the Genetec Inc. (“Genetec”) Security Center unified security platform. The integrated solutions will provide advanced people flow and occupancy management in smart spaces as well as enhanced threat detection and surveillance in high-security environments.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200630005262/en/

Quanergy’s high-performance AI-powered 3D LiDAR solution will be integrated to the Genetec unified security platform, allowing its use in multiple specialized Security Center modules including Restricted Security Area, Passenger Flow Analytics, and Occupancy Management package to help automate security, people counting and social distancing applications. Adding Quanergy’s 3D LiDAR and sensor data flow to Genetec Security Center provides increased real-time accuracy for a clearer read on actual footfall traffic, occupancy and proximity in a wide variety of industrial applications from transit systems, airports and industrial facilities to public facing businesses including banking and retail.

“Quanergy’s LiDAR flow management solutions bring a new level of real-time 3D insights that make them ideal for any environment where high accuracy and operational intelligence are critical,” said Enzo Signore, CMO at Quanergy. “Our tight integration with the Genetec Security Center unified platform enables a unique level of automation of many applications across retail, critical infrastructure, airport, seaport, enterprise, and smart cities.”

“We are excited to be integrating Quanergy's 3D LiDAR flow management solutions within Genetec Security Center,” said David Lenot, Airport Product Leader at Genetec. “By bringing their 3D LiDAR sensor data into the traffic and passenger flow modules in our unified platform, we’re helping airports and other organizations address pressing needs while also unlocking new insights into their security operations.”

Quanergy’s AI-powered LiDAR solution accurately and reliably monitor wide areas in real-time in a variety of environments without compromising people’s privacy. The new integrated 3D LiDAR-based solutions will provide:

  • 98%+ detection accuracy: Quanergy QORTEX People Counter accurately detects the number and direction of people, entering in and out of common areas. This can also be used to detect tailgating and increase the security of critical areas. QORTEX People Counter accuracy is significantly higher than camera-based system.
  • Dramatic reduction in false alarms: Quanergy’s QORTEX DTC solution significantly reduces false alarms typical of camera-based systems due to its advanced object detection, tracking, and classification capabilities.
  • 5X - 20X lower TCO (total cost of ownership) than camera-based systems due to very wide coverage (360 degree) and long range (40-70m). A single sensor can cover the area upwards of 8000 m2 . This broad area coverage also reduces installation and cabling costs.
  • Rich 3D, real-time data: Quanergy’s flow management solutions provide accurate centimeter level information about the number of objects, their spatial location, direction, and speed. Quanergy solutions also can detect distance between people to accurately monitor and manage social distancing policies.
  • Privacy protection without compromising or storing private personal information. The LiDAR solutions do not use facial recognition technology nor require opt-in by users; they therefore guarantee the anonymity of people and pose zero PII risk.
  • Reliable & Scalable: Works in all lighting and atmospheric conditions so security systems can effectively operate 24/7.

The integrated solutions are available and can be ordered immediately.

For more information, please visit us at www.quanergy.com/contact .

About Quanergy

Quanergy was founded in 2012 and builds on decades of experience of its team in the areas of optics, photonics, optoelectronics, artificial intelligence software and control systems. Headquartered in Sunnyvale, California, in the heart of Silicon Valley, Quanergy offers a high-performance AI-powered LiDAR platform designed to accelerate the automation of key business processes to increase productivity, efficiency, and safety of our 3D world. By providing actionable insights to organizations across major industries including, mapping, security, smart cities and smart spaces, industrial automation and transportation, Quanergy is enabling its partners and their end-users to deploy innovative solutions to drive their business growth and ultimately, improve the quality of life for people around the world. For more information, visit www.quanergy.com .

© Genetec Inc., 2020. Genetec, Security Center and the Genetec logo are trademarks of Genetec Inc. and may be registered or pending registration in several jurisdictions. Other trademarks used in this document may be trademarks of the manufacturers or vendors of the respective product.

Link:

ClickThru

Social Media:

https://www.facebook.com/quanergy

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Enginzyme and AGC Create Scalable Process for Key mRNA Ingredient12.1.2026 06:00:00 CET | Press release

At the mRNA Health conference in Berlin, enginzyme and AGC Inc. presented a scalable process to produce a key mRNA vaccine and therapy ingredient, N1-methylpseudouridine-5'-triphosphate (m¹ΨTP). The rapid growth of mRNA-based vaccines and therapeutics has driven significant demand for modified nucleotides like m¹ΨTP, which enhances mRNA stability and expression, while reducing immunogenicity. Enginzyme is a deep-tech company delivering optimized biomanufacturing solutions through cell-free enzyme engineering technology. AGC Inc. is a leading global player in fields spanning from architectural glass to chemicals and life science. AGC Inc. provides services in a wide range of life science fields, from synthetic pharmaceuticals and agrochemicals, to biopharmaceuticals and leading-edge cell and gene therapies, as well as messenger RNAs. The presentation in November detailed the latest collaboration between the companies, with a focus on the biomanufacturing of nucleotides for mRNA therapy,

Ant International Partners with Google’s Universal Commerce Protocol to Expand AI Capabilities12.1.2026 02:15:00 CET | Press release

Ant International, a leading global payment, digitisation, and financial technology provider, is collaborating on the launch of Google’s Universal Commerce Protocol (UCP), a new open standard for agentic commerce that works across the entire shopping journey — from discovery and buying to post-purchase support. UCP establishes a common language for agents and systems to operate together across consumer surfaces, businesses, and payment providers to enable commerce. So instead of requiring unique connections for every individual agent, UCP enables all agents to interact easily. UCP is built to work across verticals and is compatible with existing industry protocols like Agent2Agent (A2A), Agent Payments Protocol (AP2), and Model Context Protocol (MCP). “For agentic commerce to scale, it’s critical for the industry to align on a common set of standards. We are proud to have Ant International endorse the Universal Commerce Protocol as the foundation for that future,” said Ashish Gupta, VP

Torq Secures $140M Series D at $1.2B Valuation to Lead the AI SOC and Agentic AI Era11.1.2026 17:59:00 CET | Press release

Fueled by Massive Customer Adoption of AI Agents, Torq Scales the World’s First True AI SOC Platform and Accelerates Expansion into the U.S. Federal Market Torq, the established Agentic AI security operations pioneer, today announced it has closed a massive $140 million Series D funding round, propelling its valuation to $1.2 billion and total funding to $332M. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260112510774/en/ Led by Merlin Ventures—a leading cybersecurity fund renowned for its deep access to the U.S. commercial and Public Sector markets—with participation from all existing investors, including Evolution Equity Partners, Notable Capital, Bessemer Venture Partners, Insight Ventures Partners, and Greenfield Partners, this capital injection is a definitive investment in the future of security. Torq is driving the industry’s critical shift: the complete transformation of the Security Operations Center (SOC) through

Andersen udvider sine kompetencer med tilføjelsen af Scimitar9.1.2026 21:44:00 CET | Pressemeddelelse

Andersen Consulting har indgået en samarbejdsaftale med Scimitar, der er et firma med fokus på at accelerere innovation i biovidenskabsbranchen. Scimitar, der har hovedkvarter i USA, et førende konsulenthus inden for strategieksekvering for biovidenskabsbranchen. Virksomheden er specialiseret i design af driftsmodeller, digital transformation og organisatorisk forandring. Scimitar samarbejder med medicinal- og biotech-virksomheder om at accelerere innovation, styrke den driftsmæssige eksekvering og sikre compliance gennem hele produkters livscyklus. Deres praktiske og samarbejdsorienterede tilgang sikrer løsninger, der ikke blot er formålstjenlige, men også skalerbare. "Virksomheder inden for biovidenskabsbranchen befinder sig i en tid med hurtige videnskabelige fremskridt, stigende regulatorisk kompleksitet og et voksende behov for operationel agilitet, samtidig med at de holdes op mod de højeste standarder for patientsikkerhed og dataintegritet," udtaler Ramy Khalil, CEO i Scimitar.

Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C)9.1.2026 13:00:00 CET | Press release

Expanded collaboration builds on Acepodia and Biocytogen’s recent co-development efforts to evaluate selected bispecific antibody and dual-payload ADC programs Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) and Acepodia (6976:TT), today announced that the companies have entered into an option and license agreement designed to enable the structured evaluation of bispecific antibody-drug conjugate (BsADC) programs to further advance the development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs). The agreement grants Acepodia an option to obtain an exclusive worldwide license from Biocytogen for two BsADC programs. Under the terms of the agreement, Biocytogen is eligible to receive an upfront option fee and, upon Acepodia’s exercise of the option, additional payments including option exercise fees, development, regulatory, and commercial milestone payments, as well as royalties on future product sales. The financial terms of the agreem

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye